Clinical Pharmacokinetics and Pharmacodynamics of Afatinib. - Wikidata - awgldk - TriplyDB

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.

http://www.wikidata.org/entity/Q37650711

about

Afatinib ameliorates osteoclast differentiation and function through downregulation of RANK signaling pathways.Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice.Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines.The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers.Case series on the association between blood levels and side effects of afatinib maleate.Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis.

P2860

Q33649260-2D8195E8-0D60-4A57-B6C3-95B9C5FD3541 Q37642541-EAA7FC1D-B2F6-4A66-B981-42E851587E36 Q39429946-CE3F7EBD-9729-4317-B63D-559E9F044230 Q47564950-F6D94322-A7C7-4C9D-98AA-4BF529215D75 Q49602341-B0C6322C-C8FB-45FB-B7E7-9BA605F87FF1 Q51825102-6889939A-9425-4013-B87C-CB6079642696 Q52653002-26819F36-92D1-4C90-8A7A-AE76DB968D83

P2860

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.

http://www.wikidata.org/entity/Q37650711

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 July 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.

@en

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.

@nl

type

label

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.

@en

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.

@nl

prefLabel

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.

@en

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.

@nl

P1433

Q37650711-22A29D1E-DDA6-4399-808E-37004271B757

P1476

Q37650711-28D33EFB-E752-4445-9AE0-DB8E3DE98E54

P2093

Q37650711-36DEFE13-680D-4D6E-B6F2-589B3E5CFD58

Q37650711-5F791D0B-2D91-4A31-BCA6-56ACD5C10E55

Q37650711-7518D95B-B939-4129-9579-576F795CD685

Q37650711-DAF67857-442B-4649-945C-0BDB32818347

Q37650711-DB5C68BC-E664-4FBB-98BA-C488644A4E2F

P275

Q37650711-57F8B821-19F5-4D8B-981B-AC765D427CE0

P2860

Q37650711-0639A1A0-990C-4513-A15A-2F9B9093FE4C

Q37650711-0A1CB81C-61C6-43C0-9305-10125397B0AA

Q37650711-12D57C39-9F8C-4934-B3AF-4808D643F931

Q37650711-22E9659D-6B2F-4A23-93AE-0819C32B75FF

Q37650711-2CDA27E7-B03D-4548-8494-998358F41E5A

Q37650711-30BEDCCF-9F1D-44D2-BA7F-736A2A13A650

Q37650711-346FBAE5-9500-4303-8088-B1E7A5C3A534

Q37650711-358462C2-3ED3-45DF-B9B5-3595BF7C368E

Q37650711-35A84717-CC4F-4F63-923E-91D36A5BBF10

Q37650711-3EBE7BD0-3659-4044-A360-7773EA53B721

P2888

Q37650711-F2A4FC00-9753-4B9F-81C0-03AF9FFA94FD

P304

Q37650711-1093D57A-4867-4102-AECD-80A976AEED30

P31

Q37650711-9C262050-4552-472B-9343-448C84F90C26

Q37650711-FA02CD7D-A3E3-4439-A167-79F10DF4F3E9

P356

Q37650711-1C5728BF-527B-4AF3-8DDF-CB53AE85E29A

P433

Q37650711-847C8765-6102-4C5B-B3D2-8E008891BF9E

P478

Q37650711-24D39AD2-CE44-4079-8B28-30CC8C131312

P5008

Q37650711-6E7ACE77-B863-49C2-B393-437CF95DD8E5

P577

Q37650711-1254DAA2-0438-48D4-A141-21962977327B

Q37650711-78CDDF1D-29F0-4816-B0AD-7A8B53156CC4

P698

Q37650711-C1208ED7-8F48-4419-A53F-AAAC20B4107F

P921

Q37650711-336D0098-80E6-4BA4-B9E4-5F6AB6193533

Q37650711-5619BB32-E08F-4191-A205-1BF9046513A9

Q37650711-88F5CB56-B7EF-4CF0-B3E5-05F0AF9ED540

Q37650711-A7187C45-4415-4098-8918-E2830FAD660B

P932

Q37650711-E2BF3063-0667-449E-A52F-0EF3B139329E

P356

S40262-016-0440-1

P1433

Clinical Pharmacokinetics

P1476

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.

@en

P2093

David Schnell

http://www.w3.org/2001/XMLSchema#string

Matthias Freiwald

http://www.w3.org/2001/XMLSchema#string

Peter Stopfer

http://www.w3.org/2001/XMLSchema#string

Sven Wind

http://www.w3.org/2001/XMLSchema#string

Thomas Ebner

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

P2888

s40262-016-0440-1

P304

235-250

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40262-016-0440-1

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2016-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27470518

http://www.w3.org/2001/XMLSchema#string

P921

cell surface receptor

membrane proteins

P932

5315738

http://www.w3.org/2001/XMLSchema#string